1,028 results on '"Pascual‐Figal, Domingo"'
Search Results
2. Withdrawal of drug therapy in responders to cardiac resynchronization therapy: rationale and design of the REMOVE trial
3. Retirada del tratamiento farmacológico en pacientes respondedores a terapia de resincronización cardiaca: justificación y diseño del ensayo clínico REMOVE
4. Diagnosis and treatment of myocarditis and inflammatory cardiomyopathy. Consensus document of the SEC-Working Group on Myocarditis
5. Diagnóstico y tratamiento de la miocarditis y la miocardiopatía inflamatoria. Documento de consenso SEC-GT de miocarditis
6. Intubation Decision Based on Illness Severity and Mortality in COVID-19: An International Study*
7. Effectiveness and safety of non-invasive ventilation in the management of cardiogenic shock
8. Multidisciplinary Management of Patients With Chronic Obstructive Pulmonary Disease and Cardiovascular Disease
9. Clonal hematopoiesis is not prevalent in Hutchinson-Gilford progeria syndrome
10. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status
11. Value of increased soluble suppressor tumorigenicity biomarker 2 (sST2) on admission as an indicator of severity in patients with COVID-19
12. Abstract 18216: NT-proBNP After Discharge in Patients With Decompensated Heart Failure and Preserved Left Ventricle Ejection Fraction: The NICE Study
13. Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial
14. Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management
15. Consenso de expertos sobre el diagnóstico y el tratamiento de la miocarditis asociada con infección o vacunación contra el SARS-CoV-2
16. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis
17. Critical warm ischemia time point for cardiac donation after circulatory death
18. Serum potassium dynamics during acute heart failure hospitalization
19. CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia
20. Looking for the ideal medication for heart failure with reduced ejection fraction: a narrative review.
21. Evolución de los pacientes con insuficiencia cardiaca aguda secundaria a infarto agudo de miocardio tratados con ventilación mecánica no invasiva
22. The Global Ambulatory Blood Pressure Monitoring (ABPM) in Heart Failure with Preserved Ejection Fraction (HFpEF) Registry. Rationale, design and objectives
23. Clonal haematopoiesis and cardiac arrythmias: rhythm-altering mutations
24. Colchicine for the treatment of coronary artery disease
25. Registro Español de Trasplante Cardiaco. XXXII Informe Oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología
26. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction
27. Registro Español de Trasplante Cardiaco. XXXI Informe Oficial de la Asociación de Insuficiencia Cardiaca de la Sociedad Española de Cardiología
28. Pronóstico al año en pacientes con insuficiencia cardiaca en España. Registro ESC-EORP-HFA Heart Failure Long-Term
29. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study
30. Non-biopsy diagnosis of familial amyloid cardiomyopathy
31. Impact of pre-hospital renal function on the detection of acute kidney injury in acute decompensated heart failure
32. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure
33. Cambio en la causa de muerte e influencia de la mejora terapéutica con el tiempo en pacientes con insuficiencia cardiaca y fracción de eyección reducida
34. Análisis económico del tratamiento ambulatorio intermitente con levosimendán de la insuficiencia cardiaca avanzada en España
35. Incidence, prognosis and predictors of heart failure after acute myocardial infarction
36. The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI
37. Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
38. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
39. Prevalence and Prognostic Implications of Valve Disease in Patients With Atrial Fibrillation Initiating Direct Oral Anticoagulants
40. Patient-Associated Predictors of 15- and 30-Day Readmission After Hospitalization for Acute Heart Failure
41. Role of Beta-blockers in Cardiovascular Disease in 2019
42. Population-based Study of First Hospitalizations for Heart Failure and the Interaction Between Readmissions and Survival
43. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure
44. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population
45. The Possible Synergistic Pharmacological Effect of an Oral Berberine (BBR) and Curcumin (CUR) Complementary Therapy Alleviates Symptoms of Irritable Bowel Syndrome (IBS): Results from a Real-Life, Routine Clinical Practice Settings-Based Study.
46. N‐terminal pro‐B‐type natriuretic peptide post‐discharge monitoring in the management of patients with heart failure and preserved ejection fraction – a randomized trial: The NICE study.
47. Current Role of SLGT2 Inhibitors in the Management of the Whole Spectrum of Heart Failure: Focus on Dapagliflozin
48. Personalizing anti‐inflammatory therapy in heart failure: a new way
49. ST2 circulante: un patógeno, más que un biomarcador
50. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.